Savoy Pharmaceuticals, founded in 2004, is working to bring more effective and safer therapies to cancer patients by developing targeted, immunotherapies using the human immune system to treat cancers and viruses.
Funded by $2.5M in private investment, Savoy has only $600k in equity capital remaining and available to investors before the series A capital raise closes. Savoy has completed pre-clinical, IND enabling studies and is preparing to enter clinical trials for 2 of its 30+ indications. This investment will fund the remaining development of the antibody to take into clinical trials.
According to a new study by the IMS Institute for Healthcare Informatics, global oncology spending hit $91 billion last year, and it's growing 5% annually. The overall cost for cancer treatments per month in the U.S. is now $10,000, up from $5,000 just a year ago. With new cancer diagnosis reaching a projected $2B in 2020, pancreas and liver cancers are projected to surpass breast, prostate, and colorectal cancers to become the second and third leading causes of cancer-related death by 2030.
In the search for targeted therapies many scientists have turned to blood serum in the hope of identifying a chemical marker that could allow simple and accurate treatment of cancer.Like most research, those markers discovered have provided only limited success.
In pre-clinical trials, Savoy's patented novel tumor marker was found on the surface of several cancer types as well as viruses in large enough quantity to make it a viable marker for antibodies to solicit the immune system, killing cancer cells while leaving normal cells unharmed. Currently unprecedented to find a marker consistent on several different types of cancer, this finding could change the way we look at treating cancer and reduce the need for chemotherapy. Savoy is comprised of a team of MD’s, Scientists and MBA's with backgrounds from UCLA, University of Rochester, BYU, MD Anderson, Roche, and Genentech.